Narayana Hrudaya
Narayana Hrudaya Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
Not discussed on this call: order book.
The short version
India hospital business shows strong revenue growth driven by a combination of increased footfalls and ARPOB (Average Revenue Per Occupied Bed). Debt levels expected to rise for the next 2-3 years due to project construction but anticipated to reduce by FY30, improving financials.
From Narayana Hrudaya's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- India hospital business shows strong revenue growth driven by a combination of increased footfalls and ARPOB (Average Revenue Per Occupied Bed).
- Clinics contribute significantly, with OP consults growing about 30% YoY and 66,000 consultations in Q1, supporting hospital footfalls and overall revenue.
- Expansion plans include adding new beds, such as the Southwest Bangalore project expected to start by end of Q2 FY27.
- Focused capital deployment in clusters where the company already has presence, with possible new geographic markets considered after Phase 1 progress.
- Efforts to change payer mix in the UK from mainly NHS to a more balanced one with private and self-pay revenues, expected to increase private contribution over time.
- Insurance business is growing despite current losses, with initiatives underway to improve underwriting, claims management, and profitability as the book scales.
- Margin expansion expected through operational efficiencies, technology adoption, and standardized consumables and implants.
Profitability & Margins
See what Narayana Hrudaya said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has an outlined capital deployment plan focused on expansion within clusters where they already have a strong presence, over the next 3 financial years.
- Projects include hospital expansions such as the North Bangalore project, prioritized in their second round of expansion.
- Some projects have been postponed slightly due to partner-related licensing delays but remain within acceptable timeframes.
- The Southwest Bangalore 100-bed project is expected to start by end of Q2 FY27.
- Capital investment will continue with a focus on affordable care philosophy, balancing leverage benefits, new growth verticals like integrated care, and customer returns.
- The UK business acquisition involves no significant further capital deployment currently; focus is on improving earnings from existing capital.
- Longer regulatory timelines for medical software certifications in the UK add approximately 4-6 months to plans but are a one-time effort.
- The insurance business is investing in AI and claims management tools to improve sustainability but is currently small scale.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Narayana Hrudaya said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders for Narayana Hrudayalaya Limited.
- Capital deployment and expansion plans are outlined over the next 3 financial years focused on clusters with existing strong presence.
- A few projects have been postponed from FY28 to FY29 and FY30 due to minor delays such as licensing issues, mostly within acceptable timelines.
- The Southwest Bangalore 100-bed project is expected to be operational by end of Q2 FY27.
- The company continues to monitor project timelines closely and expects that most will proceed as planned.
- No specific quantitative data related to order book or pending orders is available in the provided pages.
Narayana Hrudaya — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.6K Cr, net profit ₹224 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Narayana Hrudayalaya Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Manipal Health Enterprises Ltd (Q1 FY27)
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
- Fortis Healthcare Ltd (Q1 FY27)
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
- Metropolis Healthcare Ltd (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
- Apollo Hospitals Enterprise Ltd (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
Frequently Asked Questions
What were Narayana Hrudaya Q1 FY27 results?
India hospital business shows strong revenue growth driven by a combination of increased footfalls and ARPOB (Average Revenue Per Occupied Bed). Debt levels expected to rise for the next 2-3 years due to project construction but anticipated to reduce by FY30, improving financials.
What is Narayana Hrudaya share price analysis?
Narayana Hrudaya currently shows a below-average growth signal. The stock trades at a P/E of 43.0 with a market cap of ₹37,108 Cr. Investors should review the full earnings analysis for detailed insights.
Is Narayana Hrudaya planning capital expenditure?
The company has an outlined capital deployment plan focused on expansion within clusters where they already have a strong presence, over the next 3 financial years.
Keep Narayana Hrudaya on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.